The rising prevalence in GLP-1 agonists for diabetes has sparked a debate about application forms : patches versus pills . Usually , GLP-1 therapies were solely available in oral form, but the emergence https://emilieftim030918.blogozz.com/39796232/glp-1-transdermal-delivery-systems-vs-oral-medications-is-suitable-for-the-patient